A guide to Mucosal Melanomas of the Head & Neck Histopathology Reporting

Includes the International Collaboration on Cancer reporting dataset denoted by *

<table>
<thead>
<tr>
<th>Clinical details</th>
<th>Microscopic findings</th>
</tr>
</thead>
</table>
| **S1.02** Clinical info. on request form (complete as narrative or use the structured format below) | **S3.01** *Histological tumour type*  
Cannot be assessed, specify  
OR  
Mucosal melanoma  
Melanoma (uncertain origin), specify/ comment |
|  | **G3.01** *Histological subtypes*  
Balloon cell melanoma  
Mixed epithelioid and spindle cell melanoma  
Epithelioid cell melanoma  
Spindle cell melanoma  
Amelanotic melanoma  
Desmoplastic melanoma  
Neurotropic Other, specify |
| **G1.01** Copy to doctor | **G3.02** Microscopic tumour size  
__x__x__mm |
| **S1.03** Pathology accession number | **G3.03** Perineural invasion  
Not identified  
Present  
Cannot be assessed, specify |
| **S1.04** Principal clinician | **G3.04** Lymphovascular invasion  
Not identified  
Present  
Cannot be assessed, specify |
| **G1.02** Other relevant details | **G3.05** Mitotic count  
__/mm² |
| **G1.03** | **G3.06** Ulceration  
Present  
Not identified |

**Macroscopic findings**

| **S2.01** Specimen labelled as | Text |
| **S2.02** *Operative procedure*  
*If a neck dissection is submitted, then a separate dataset is used to record the information.* | Not specified  
OR  
Biopsy (excisional, incisional), specify  
Resection, specify  
Neck (lymph node) dissection*, specify  
Other, specify |
| **S2.03** *Specimens submitted* | Not specified  
OR  
Anatomic site, specify |
| **S2.04** *Tumour site* | See p2 |
| **G2.01** *Tumour focality* | Cannot be assessed, specify  
Unifocal  
Multifocal, specify number of tumours in specimen |
| **S2.05** *Maximum dimension of largest tumour* (largest focus in a single specimen) | Cannot be assessed, specify  
OR  
__mm |
| **G2.02** *Additional dimensions of largest tumour* | __x__mm |
| **S2.06** Ink application and block identification key | Text |
| **G2.03** Additional macroscopic comments | Text |

**S3.02** *Margin status*  
Malignant melanoma  
Invasive melanoma  
Distance of invasive melanoma from closest margin  
Closest margin  
Margin(s) involved  
Melanoma in situ  
Distance of melanoma in situ from closest margin  
Closest margin  
Margin(s) involved  
Coexistent pathology  
None identified  
OR  
Melanoma in situ / pagetoid spread  
Melanosis  
Other, specify
Ancillary test findings

**G4.01** Ancillary studies
Not performed
Performed, describe

Synthesis and overview

**S5.01** *PATHOLOGICAL STAGING* See p2
**S5.02** Year of publication & edition of cancer staging system
Text
**G5.01** Diagnostic summary
Include: Specimen(s) submitted; Tumour type/subtype; Tumour stage
Text
**S5.03** Overarching comment
Text
**G5.02** Edition/version of RCPA protocol
Text

---

**S2.04 Tumour site**

Cannot be assessed
OR

Select all that apply
- Sinonasal, specify subsite(s)
  - Left
  - Midline
  - Right
  - Laterality not specified
- Oral cavity, specify subsite(s)
  - Left
  - Midline
  - Right
  - Laterality not specified
- Larynx, specify subsite(s)
  - Left
  - Midline
  - Right
  - Laterality not specified
- Other, specify site/subsite(s)
  - Left
  - Midline
  - Right
  - Laterality not specified
- Other, specify including laterality

---

**S5.01 Pathological Staging (AJCC 8th Ed.)**##

m - multiple tumours
y - post therapy
r - recurrent

**Primary Tumour (T)**

**T3** Tumours limited to the mucosa and immediately underlying soft tissue, regardless of thickness or greatest dimension; for example, polypoid nasal disease, pigmented or nonpigmented lesions of the oral cavity, pharynx, or larynx.

**T4a** Moderately advanced or very advanced
Tumour involving deep soft tissue, cartilage, bone, or overlying skin.

**T4b** Very advanced disease. Tumour involving brain, dura, skull base, lower cranial nerves (IX, X, XI, XII), masticator space, carotid artery, prevertebral space, or mediastinal structures

## Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Eighth Edition (2016) published by Springer Science and Business Media LLC. www.springerlink.com